Navigation Links
Inovio's Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
Date:6/14/2013

an mix and match these individual DNA plasmid constructs as desired to create vaccine candidates. Inovio has previously reported human data indicating protective immune responses against the subtypes H1N1 and H5N1.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical stud
'/>"/>

SOURCE Inovio Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Finesse Solutions Launches Next Generation G3Lab Universal SmartControllers to Enhance Productivity in Bench Scale Cell Culture and Fermentation
2. Flexpoint Announces Universal Settlement Involving the Medical Bed and Related Technologies
3. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
4. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
5. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
6. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
7. ASCO Interview of MD Andersons Mittendorf on AE37 Breast Cancer Vaccine Now Available on Generex Websites
8. Adult and Adolescent Vaccines Market to 2018 Report - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
9. Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients
10. Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
11. Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Elekta (NSE:EKTAb) and Royal Philips ... Foundation Trust ( Manchester, UK ), a ... is to develop the clinical value of an integrated ... a system would, in principle, improve the practice of ... "The Christie was an essential participant in the ...
(Date:7/22/2014)... 2014 Sanofi Pasteur, the vaccines division of Sanofi ... that the first lots of Fluzone ® (Influenza Vaccine) ... by the U.S. Food and Drug Administration (FDA) for distribution. ... first of at least 65 million doses of seasonal influenza ... U.S. health care providers and pharmacies in August. ...
(Date:7/22/2014)... SAN DIEGO , July 22, 2014  Halozyme ... that it has resumed enrollment and dosing of patients ... PEGPH20 in patients with pancreatic cancer under the revised ... PEGPH20 is an investigational PEGylated form of Halozyme,s proprietary ... of tumors that accumulate hyaluronan. "Our ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
... ALL Study Group Presented Data at the 14th Congress ... in Patients with Minimal Residual Disease , , ... MITI ), a biopharmaceutical company developing novel, proprietary antibodies ... announced that the German Multicenter ALL Study Group (GMALL) ...
... 2 data sets to be released-- , ... clinical trials in patients with blepharospasm and cervical dystonia -- ... -- were presented at the Movement Disorder Society (MDS) 13th ... by Merz Pharmaceuticals, which plans to file a Biologic License ...
Cached Medicine Technology:Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 2Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 3Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 5Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
(Date:7/23/2014)... Hemodialysis equipment is the most widely used ... acute or chronic renal failure. , The Chinese hemodialysis ... European, American and Japanese enterprises. In 2013, the import ... growing demand for hemodialysis equipment in China, its import ... in 2009-2013. Germany, Sweden and Japan as the main ...
(Date:7/23/2014)... month of July, LunaDress, a well-known wedding dress manufacturer and ... hosting a couple of promotions on its website. Recently, the ... wedding dresses for the UK market . The fresh range ... are now offered with huge discounts, from 20 to 70 ... suppliers, LunaDress is always making full efforts to offer classy ...
(Date:7/23/2014)... 23, 2014 World Gardens Café, the ... healthy gourmet cuisine, received rave reviews last week when ... Mixer. Mixer attendees were amazed that healthy food could ... World Gardens Café, the premier provider of delicious and ... booth at Dave Linden’s LA’s Largest Mixer. Attendees who ...
(Date:7/23/2014)... 2014 Sanuvox has produced a ... of the company’s latest system designed for hospital ... System uses a primary and secondary unit to ... ‘C’ energy controlling (6 log reduction) drug-resistant microorganisms ... than 10 minutes in a standard patient hospital ...
(Date:7/23/2014)... Low enrollment and higher-than-expected administrative costs ... up with alternative means to becoming self-sustaining. Industry ... accomplish this in the July 17 issue of ... , “We never expected the operating budgets would ... an attorney at the law firm Venable LLP ...
Breaking Medicine News(10 mins):Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 2Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 3Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 4Health News:LunaDress Continues To Enrich Product Line By Offering Short Summer Beach Wedding Dresses 2Health News:Healthy Food Gets Rave Reviews at LA’s Largest Mixer 2Health News:Sanuvox Produces ASEPTIX² Movie Showcasing the Feature Benefits of the Company’s Latest Flagship Hospital Surface Disinfection System 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3
... from the University of North Carolina at Chapel Hill suggests that ... morning or later in the afternoon can influence the onset ... exposure to UV radiation in the morning increased the risk of ... Although mice and humans both reside on a 24-hour day, the ...
... Rockville, MD -- Physical activity may be what the ... developing glaucoma. According to a recently published scientific paper, ... long-term beneficial impact on low ocular perfusion pressure (OPP), ... the Investigative Ophthalmology & Visual Science journal ...
... LANSING, Mich. -- Despite the fact mental health problems ... combined, about two-thirds of mental health patients are cared ... Additionally, even larger numbers of other patients regularly ... A new five-year, $1 million grant allows Michigan State ...
... related macular degeneration (AMD) is the leading cause of ... identified several relatively common genetic variants which together predict ... number of persons without the disease also have these ... able to clearly show a specific rare mutation called ...
... study published today in the journal Nature Genetics ... Lieb, PhD, present experiments supporting a longstanding hypothesis that ... of the X chromosome. The finding provides clarity to ... with more information to interpret experiments involving genetic measurements ...
... FESC, from the University of Padua, Italy, explains, "To ... from all the different imaging modalities, not just Echo. ... is that we want to become more patient oriented, ... the most appropriate technology to address individual clinical questions." ...
Cached Medicine News:Health News:Morning UV exposure may be less damaging to the skin 2Health News:Physical fitness could have a positive effect on eye health 2Health News:Residency program focuses on overlooked mental health needs 2Health News:Researchers ID genetic mutation associated with high risk of age-related macular degeneration 2Health News:Study confirms males and females have at least 1 thing in common: Upregulating X 2Health News:Congress alert: EUROECHO and Other Imaging Modalities: New patient emphasis 2Health News:Congress alert: EUROECHO and Other Imaging Modalities: New patient emphasis 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: